XCell Therapeutics Inc is a Korea-based company primarily engaged in the manufacture and distribution of cell culture mediums. The Company is mainly engaged in the provision of dermal papilla cells (DPC), keratinocytes, exosomes and other dedicated mediums. Additionally, the Company is engaged in the manufacture and distribution of virus transport mediums. The Company sells its products in domestic and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-09-11	₩1,016.00	+1.60%	45,875
26-09-10	₩1,000.00	0.00%	53,605
26-09-09	₩1,000.00	-1.67%	231,727
26-09-08	₩1,017.00	-7.96%	456,900
26-09-07	₩1,105.00	-0.09%	103,811

End-of-day quote Korea S.E.

More quotes

End-of-day quote Korea S.E. 2026-09-11			5-day change	1st Jan Change
1,016.00 ^KRW	+1.60%		-8.14%	-38.83%

25-08-14	Xcell Therapeutics to conduct capital increase of 15 billion won	RE
24-11-21	Gencurix Inc. announced that it expects to receive KRW 899.999158 million in funding from Xcell Therapeutics Inc.	CI

Market Cap	17.57B 13.11M 11.29M 10.69M 9.69M 18.18M 1.25B 18.28M 127M 48.84M 637M 49.23M 48.15M 2.01B	P/E 2024	-4.26x	P/E 2025	-1.77x
Enterprise Value	16.15B 12.05M 10.38M 9.83M 8.91M 16.72M 1.15B 16.8M 117M 44.9M 586M 45.25M 44.26M 1.85B	EV / Sales 2024	21.3x	EV / Sales 2025	14x
Free-Float	88.23%	Yield 2024 *	-	Yield 2025	-

25-08-14	Xcell Therapeutics to conduct capital increase of 15 billion won	RE
24-11-21	Gencurix Inc. announced that it expects to receive KRW 899.999158 million in funding from Xcell Therapeutics Inc.	CI
24-07-16	Xcell Therapeutics Shares Fall 4.7% Below Offering Price on Kosdaq Debut	MT
24-07-08	Xcell Therapeutics Inc. has completed an IPO in the amount of KRW 16.18 billion.	CI

1 day	+1.60%
1 week	-8.14%
Current month	-14.77%
1 month	-26.59%
3 months	-29.93%
6 months	-27.43%
Current year	-38.83%

Xcell Therapeutics Inc. Stock

Stocks

A373110

KR7373110006

Pharmaceuticals

Valuation : Xcell Therapeutics Inc.

Chart: Xcell Therapeutics Inc.

Latest news : Xcell Therapeutics Inc.

News in other languages : Xcell Therapeutics Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Xcell Therapeutics Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 week	964	1,125
1 month	964	1,482
Current year	964	2,050
1 year	964	4,035
3 years	964	12,900
5 years	964	12,900
10 years	964	12,900

Manager	Title	Age	Since
U-Ri Lee CEO	Chief Executive Officer	54	2016-08-31
Soo-Rim Oh COO	Chief Operating Officer	65	-
Hae-Min Jeong CTO	Chief Tech/Sci/R&D Officer	40	-

Director	Title	Age	Since
U-Ri Lee BRD	Director/Board Member	54	2016-08-31
Hae-Min Jeong BRD	Director/Board Member	40	-
Mahn-Soon Hwang BRD	Director/Board Member	56	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
XCELL THERAPEUTICS INC.	+1.60%	-8.14%	-63.97%	-	13.11M
ELI LILLY AND COMPANY	-0.65%	-2.93%	+47.70%	+86.17%	994B
JOHNSON & JOHNSON	-0.29%	-3.51%	+49.15%	+62.35%	640B
ABBVIE INC.	+0.83%	+0.26%	+17.76%	+72.25%	454B
ROCHE HOLDING AG	-0.38%	-3.59%	+30.13%	+35.17%	337B
NOVARTIS AG	-0.09%	-13.54%	+13.34%	+24.95%	261B
ASTRAZENECA PLC	-0.43%	-2.48%	-0.73%	+9.58%	246B
AMGEN INC.	-1.34%	-13.70%	+36.53%	+44.96%	204B
NOVO NORDISK A/S	-3.44%	-7.51%	-20.63%	-59.44%	190B
GILEAD SCIENCES, INC.	-0.75%	-4.82%	+25.46%	+87.14%	178B
Average	-0.49%	-5.99%	+13.48%	+40.35%	350.48B
Weighted average by Cap.	-0.51%	-4.42%	+30.96%	+54.95%

	2024	2025
Net sales	1.93B 1.44M 1.24M 1.18M 1.07M 2M 138M 2.01M 13.98M 5.38M 70.14M 5.42M 5.3M 222M	1.95B 1.45M 1.25M 1.19M 1.08M 2.02M 139M 2.03M 14.09M 5.42M 70.67M 5.46M 5.34M 223M
Net income	-9.54B -7.12M -6.13M -5.81M -5.26M -9.88M -680M -9.93M -68.98M -26.53M -346M -26.74M -26.15M -1.09B	-10.93B -8.15M -7.02M -6.65M -6.03M -11.31M -779M -11.37M -78.99M -30.37M -396M -30.61M -29.94M -1.25B
Net Debt	-3.1B -2.31M -1.99M -1.89M -1.71M -3.21M -221M -3.22M -22.41M -8.62M -112M -8.69M -8.5M -355M	-1.42B -1.06M -912K -864K -783K -1.47M -101M -1.48M -10.26M -3.95M -51.47M -3.98M -3.89M -163M